A1M Pharma: A bright future ahead
We initiate coverage of A1M Pharma, an early stage biotech company developing a candidate to treat acute kidney injuries in associating with cardiac surgery. With a history of disappointment we now see real potential in A1M Pharma with their new management and strategy as they move towards meeting an unmet medical need. With a strong owner base and positive data from their first phase I study, we see a bright future ahead.